证券代码：300573 证券简称：兴齐眼药 公告编号：2025-042 沈阳兴齐眼药股份有限公司 2、现场会议时间：2025年9月15日（星期一）下午14:30。 3、网络投票时间：2025年9月15日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年9月15日9:15—9:25，9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年9月15 日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市浑南区泗水街68号，沈阳兴齐眼药股份有限 公司E1号楼，二楼多功能厅。 5、会议召集人：公司董事会。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2025 年第二次临时股东大会决议公告 6、会议主持人：公司董事长刘继东先生。 7、股东出席情况： 出席本次股东大会现场会议和网络投票的股 ...

Group 1 - The "Quality Month" event in Liaoning Province was launched on September 10, 2025, focusing on brand building and high-quality development with the theme "Brand Power, Quality Wins the Future" [1] - The event served as a platform for discussing new paths for quality and brand work in the province, gathering various stakeholders [1] Group 2 - Several companies were recognized as "Liaoning Excellent Products," including Benxi Longshan Spring Beer Co., Ltd. and Huludao Yifeng (Group) Sportswear Co., Ltd. [3] - Other companies nominated for the "Liaoning Excellent Products" title included Shenyang Xingqi Eye Medicine Co., Ltd., Dayang Group, Liaoning Sangou Liquor Co., Ltd., and Liaoning Lingxiushan Shenghui Industrial Group Co., Ltd. [3] Group 3 - Shenyang Xingqi Eye Medicine Co., Ltd. shared the story of developing China's first cyclosporine eye drops for dry eye treatment after 18 years of research [5] - Dayang Group recounted its journey from employing 85 rural women to aiming to create the best suits in China and the world [5] - Benxi Longshan Spring Beer Co., Ltd. highlighted its commitment to quality and technological innovation in a competitive market [5] Group 4 - Liaoning Sangou Liquor Co., Ltd. emphasized its core value of "openness" through multiple reforms, enhancing its brand's historical significance [7] - Liaoning Lingxiushan Shenghui Industrial Group Co., Ltd. shared its health-oriented product development strategy to differentiate itself from industry giants [7] - Huludao Yifeng (Group) Sportswear Co., Ltd. narrated its evolution from a small vendor to a complete industry chain through technological innovation [7]

Core Insights - The event "Quality Month" in Liaoning Province was launched on September 10, 2025, focusing on brand building and high-quality development under the theme "Brand Synergy, Quality Wins the Future" [1] - The conference released the 2025 brand value evaluation results and the "Liaoning Province Quality Status White Paper (2024)", showcasing the improvement in brand competitiveness across key industries and enterprises in the province [1] - Representatives from 15 enterprises shared their brand growth stories, highlighting the innovative spirit and responsibility of Liaoning brands [1] Summary by Categories Brand Development - The event emphasized the importance of brand building in achieving high-quality development in Liaoning Province [1] - The theme of the conference, "Brand Synergy, Quality Wins the Future," reflects a strategic focus on enhancing brand value [1] Quality Assessment - The release of the 2025 brand value evaluation results provides a clear view of the competitive landscape among key industries and enterprises in Liaoning [1] - The "Liaoning Province Quality Status White Paper (2024)" summarizes the progress made in quality infrastructure and regulatory services over the past year [1] Case Studies - Companies such as Shenyang Xingqi Eye Pharmaceutical Co., Danyang Group, Anshan Falan Co., and Geerlao New Materials Co. presented their brand development experiences [1] - These case studies serve to illustrate the innovative approaches and commitments of Liaoning enterprises towards brand enhancement [1]

每经AI快讯，有投资者在投资者互动平台提问：公司的低浓度阿托品需求旺盛，随着行业渗透率的提 升，公司的产能能否满足市场需求？公司有无扩产计划？ 兴齐眼药（300573.SZ）9月9日在投资者互动平台表示，截至目前公司有多条生产线具备生产0.01%硫酸 阿托品滴眼液的GMP资质，可以满足市场需求。公司将密切关注市场需求变化，及时做好产能安排。 （文章来源：每日经济新闻） ...

转自：中国质量报 □ 本报记者 乔燕强 2024年"质量月"活动成功举办后，兴齐眼药立即组织开展了2025年质量活动的工作策划。该公司总经理 高峨为了更好地开展质量活动，将"质量月"打造成公司质量文化标签，提出将"质量月"升级成"质量 季"，用"季"的概念突出质量在企业管理中的重要程度，让每项质量活动从策划、到举办、再到成果展 示，都能体现出更好的效果。这样，员工能有充分的时间参与，同时也避免该公司与行业协会等单位的 活动时间发生冲突。 今年8月，兴齐眼药成立"质量季"活动策划核心小组，用整整一个月的时间来筹备。在活动内容发布会 上，兴齐眼药首席质量官薛晓柏介绍了"质量季"中的"季"借用毕业季、赛季中"季"的含义，是指以9月 全国"质量月"为起始的、集中开展质量活动的两三个月时间段，具体时长要根据每年的实际情况和活动 策划来定。今年集中在9月和10月。此次活动内容围绕4个维度展开：质量文化塑造方面设计有高层管理 讲文化、班组设计LOGO大赛、质量管理模式发表等活动；质量能力提升方面设计有质量大讲堂、专项 知识竞赛、6项技能大比武；质量创新实践方面设计有职能技术赋能管理实践、改进创新活动分享等； 质量成果推广方 ...

昨日基金共对26家公司进行调研，扎堆调研恺英网络、兴齐眼药、我武生物等。 证券时报·数据宝统计，9月1日共43家公司被机构调研，按调研机构类型看，基金参与26家公司的调研 活动，其中，5家以上基金扎堆调研公司共12家。恺英网络最受关注，参与调研的基金达34家；兴齐眼 药、博思软件等分别获24家、9家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有11家，创业板公司有10家，沪市主板公司有 2家，科创板公司有2家，北交所公司有1家。所属行业来看，基金调研的公司共涉及17个行业，所属电 力设备、电子、医药生物等行业个股最多，均有3只个股上榜。 市场表现上，基金调研股中，近5日上涨的有10只，涨幅居前的有坤恒顺维、兴齐眼药、华力创通等， 涨幅为15.13%、14.77%、14.39%；下跌的有16只，跌幅居前的有广信科技、祥生医疗、珠城科技等， 跌幅为8.37%、7.83%、7.57%。 数据宝统计，基金参与调研股中，近5日资金净流入的有7只，博杰股份近5日净流入资金1.12亿元，主 力资金净流入最多；净流入资金较多的还有三晖电气、蒙娜丽莎等，净流入资金分别为8267.21万元、 5085.94 ...

Summary of the Conference Call for Xingqi Eye Pharmaceutical Company Overview - **Company**: Xingqi Eye Pharmaceutical - **Industry**: Ophthalmic Pharmaceuticals Key Financial Performance - **Revenue**: 11.62 billion CNY in H1 2025, a year-on-year increase of 30.38% [2][3] - **Net Profit**: 3.35 billion CNY, a year-on-year increase of 97.75% [2][3] - **Dividend Proposal**: Cash dividend of 7 CNY per 10 shares, subject to shareholder approval [2][3] Research and Development Progress - **R&D Investment**: 1.0 billion CNY, an increase of 8.11%, representing 8.64% of revenue [2][4] - **Product Approvals**: - Heafluprost eye drops approved - Lidocaine eye gel in Phase III clinical trials - SQ22,031 eye drops in Phase II clinical trials for neurotrophic keratitis, listed as a rare disease drug [2][4][5] - **Innovative Products**: - 60 approved ophthalmic drugs, with 38 in the medical insurance directory and 6 in the national essential drug list [4] - SQ22,031 eye drops and SQ129 vitreous sustained-release injection under development [9] Market Strategy and Sales Performance - **Atropine Sales**: - Widely distributed in public hospitals and major private groups, covering nearly 17,000 retail pharmacies and online platforms [2][10] - Sales growth driven by a comprehensive marketing strategy and collaboration in myopia prevention [12] - **Sales Team**: Over 500 professional promotion specialists, with plans for further expansion based on market conditions [10][12] - **Market Coverage**: - Multi-channel marketing strategy including both online and offline channels [12][18] - Focus on enhancing brand influence and customer satisfaction [7][8] Future Outlook and Market Trends - **Market Potential**: - Significant growth potential in the myopia prevention market, with over 100 million schoolchildren affected [24] - Anticipated stable gross margin due to increased sales scale and operational efficiency [21] - **Product Pipeline**: - Continued focus on innovative drug development in ophthalmology, including treatments for myopia, dry eye, and other eye diseases [23][25] - Plans to expand into international markets with existing and new products [22] Additional Insights - **Quality Management**: - Achieved national-level green factory certification and implemented stringent quality control measures [6] - **Patient Compliance**: - High compliance rates among pediatric patients using atropine, with ongoing efforts to improve disease education and treatment adherence [18][19] - **Clinical Guidelines**: - Received endorsements from multiple clinical guidelines, enhancing the credibility of products like cyclosporine eye drops [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, R&D advancements, market strategies, and future outlook for Xingqi Eye Pharmaceutical.

3）麦澜德 （呈瑞投资参与公司特定对象调研） 调研纪要：2025年上半年，公司实现营收2.41亿元，同比增长5.62%；归母净利润6,392.01万元，同比下 降11.96%，主因处置子公司不良资产。生殖康复和抗衰业务收入7,983.87万元，同比增长42.45%。毛利 率下降因新品推广策略调整及大客户订单增加。公司聚焦非侵入式脑机接口，已在多模态生理信号采集 等领域形成技术积累。情感交互产品已形成原理样机，计划年内开展临床预实验。多中心临床研究助力 产品进院。海外业务主推东南亚市场。康美中心今年目标在江浙打造样板。公司坚持"一端更严肃，一 端更消费"战略，推动双轮驱动。 机构简介： 上海呈瑞管理有限公司2010年5月成立于上海，注册资金1100万。公司于2014年4月登记为私募投资基金 管理人，2015年3月成为中国证券投资基金业协会观察会员。公司主营二级市场，涵盖大类资产配置， 主要策略包括宏观对冲策略，高频Alpha策略，CTA策略，策略平台均属自行开发运行，多年以来稳健 发展，公司不断受到市场广泛认可，客户群体不断多元化，涵盖银行资管、私行、券商、保险、信托、 各类fof机构和央企等客户青睐。目前公司 ...

Group 1: Company Highlights - Changchun High New has made breakthrough progress in using AI large models to design highly alkaline single-domain antibodies, successfully completing the development of a protein product that has entered 5000-liter scale production [1] - Zhongchuang Zhiling's subsidiary Zhengmeiji Shuyun Intelligent Technology has invested heavily in building a robotic welding laboratory, promoting the transition of welding technology from manual to intelligent [2] - BoRui Pharmaceutical has submitted IND applications for BGM0504 and BGM1812 for weight loss indications in both the US and China, with BGM0504 entering Phase I clinical trials approved by the FDA [3] - Xingqi Eye Medicine's SQ-22031 eye drops, an innovative drug for treating neurotrophic keratitis and dry eye syndrome, have completed Phase I clinical trials [4] - Sunshine Nuohe reported a revenue of 7.3371 million yuan from equity-sharing projects, a year-on-year increase of 119.73%, with clinical business revenue reaching 279 million yuan, a 29% increase year-on-year [5] Group 2: Investment Management Overview - Shanghai Danyi Investment Management Partnership, established in April 2015, has a paid-in capital of 10 million yuan and is registered with the Asset Management Association of China [5] - The core executives of the company have over ten years of investment research experience, having previously worked as investment managers or chief researchers at prominent institutions [5]

Core Viewpoint - The A-share ophthalmology medical concept stocks experienced a collective surge, with several companies reaching their daily limit up, indicating strong market interest and potential growth in the sector [1][2]. Group 1: Stock Performance - Companies such as Shapais, Innovation Medical, and Xingqi Eye Medicine saw significant stock price increases, with Xingqi Eye Medicine rising over 14% and Shapais reaching a limit up [1][2]. - The ophthalmology sector index rose by 2.17%, reflecting overall positive sentiment in the market [2]. Group 2: Market News - Recent rumors indicated that the Henan Provincial Eye Hospital would stop supplying its self-made 0.01% atropine sulfate eye drops due to the expiration of its registration, which has led to increased attention on the market for similar products [3][4]. - The hospital confirmed that the 0.01% atropine sulfate eye drops had ceased production since December of the previous year, with current sales being from existing inventory [3]. Group 3: Product and Market Dynamics - Atropine sulfate eye drops have gained recognition as a "myopia miracle drug," particularly for children aged 6 to 12, and are recommended in various authoritative guidelines for myopia management [4]. - Xingqi Eye Medicine's atropine sulfate eye drops received approval for market entry in March 2024, leading to a significant increase in its stock price and revenue growth [4]. - In 2024, Xingqi Eye Medicine reported a revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [4]. Group 4: Competitive Landscape - The market for atropine sulfate eye drops is becoming increasingly competitive, with several companies, including Zhaoke Ophthalmology and Hengrui Medicine, advancing their own products [5]. - Shapais is also in the process of developing its own version of atropine sulfate eye drops, which is currently in Phase III clinical trials [5]. - Xingqi Eye Medicine is expected to continue its upward trajectory with ongoing product iterations and new submissions for market approval [5].